| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
|
JAMA
|
2010
|
9.26
|
|
2
|
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
|
N Engl J Med
|
2003
|
2.64
|
|
3
|
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
|
J Acquir Immune Defic Syndr
|
2004
|
2.55
|
|
4
|
HIV and syphilis: when to perform a lumbar puncture.
|
Sex Transm Dis
|
2007
|
2.35
|
|
5
|
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
|
J Acquir Immune Defic Syndr
|
2004
|
2.11
|
|
6
|
Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.
|
J Virol
|
2007
|
1.68
|
|
7
|
Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy.
|
AIDS
|
2006
|
1.65
|
|
8
|
Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003).
|
Enferm Infecc Microbiol Clin
|
2006
|
1.59
|
|
9
|
Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
|
Lancet
|
2004
|
1.59
|
|
10
|
Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality.
|
Diagn Microbiol Infect Dis
|
2008
|
1.58
|
|
11
|
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
|
AIDS
|
2012
|
1.46
|
|
12
|
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
|
J Acquir Immune Defic Syndr
|
2007
|
1.43
|
|
13
|
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
|
Enferm Infecc Microbiol Clin
|
2004
|
1.42
|
|
14
|
Considerations about the value of sonography for the measurement of regional body fat.
|
AIDS
|
2006
|
1.41
|
|
15
|
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
|
AIDS
|
2010
|
1.39
|
|
16
|
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
|
Antivir Ther
|
2007
|
1.33
|
|
17
|
Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
|
J Infect Dis
|
2005
|
1.32
|
|
18
|
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
|
Antimicrob Agents Chemother
|
2008
|
1.23
|
|
19
|
Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
|
Antimicrob Agents Chemother
|
2007
|
1.21
|
|
20
|
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
|
AIDS
|
2010
|
1.17
|
|
21
|
Glutamate released by dendritic cells as a novel modulator of T cell activation.
|
J Immunol
|
2006
|
1.16
|
|
22
|
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
|
J Acquir Immune Defic Syndr
|
2009
|
1.16
|
|
23
|
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
|
Vaccine
|
2011
|
1.15
|
|
24
|
Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression.
|
J Infect Dis
|
2002
|
1.11
|
|
25
|
Cardiovascular disease and HIV infection: host, virus, or drugs?
|
Curr Opin Infect Dis
|
2009
|
1.09
|
|
26
|
Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens.
|
Diagn Microbiol Infect Dis
|
2006
|
1.09
|
|
27
|
Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression.
|
PLoS One
|
2010
|
1.08
|
|
28
|
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.
|
J Virol
|
2011
|
1.06
|
|
29
|
Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
|
Clin Infect Dis
|
2004
|
1.02
|
|
30
|
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
|
AIDS
|
2003
|
0.99
|
|
31
|
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
|
J Acquir Immune Defic Syndr
|
2009
|
0.99
|
|
32
|
Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence.
|
Mod Pathol
|
2005
|
0.99
|
|
33
|
Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation.
|
J Infect Dis
|
2007
|
0.99
|
|
34
|
Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study.
|
Enferm Infecc Microbiol Clin
|
2011
|
0.98
|
|
35
|
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
|
Hepatology
|
2004
|
0.98
|
|
36
|
Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients.
|
AIDS Res Hum Retroviruses
|
2009
|
0.97
|
|
37
|
Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.
|
J Acquir Immune Defic Syndr
|
2002
|
0.97
|
|
38
|
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
|
J Infect Dis
|
2003
|
0.95
|
|
39
|
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study.
|
AIDS
|
2003
|
0.95
|
|
40
|
Human immature monocyte-derived dendritic cells produce and secrete alpha-defensins 1-3.
|
J Leukoc Biol
|
2007
|
0.93
|
|
41
|
Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells.
|
J Leukoc Biol
|
2010
|
0.92
|
|
42
|
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.
|
J Virol
|
2010
|
0.91
|
|
43
|
Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2002
|
0.90
|
|
44
|
Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.
|
J Med Chem
|
2010
|
0.90
|
|
45
|
Inflammatory responses in blood samples of human immunodeficiency virus-infected patients with pulmonary infections.
|
Clin Diagn Lab Immunol
|
2004
|
0.89
|
|
46
|
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2004
|
0.88
|
|
47
|
Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients.
|
AIDS Res Hum Retroviruses
|
2007
|
0.85
|
|
48
|
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
|
AIDS
|
2014
|
0.85
|
|
49
|
Impact of alpha-defensins1-3 on the maturation and differentiation of human monocyte-derived DCs. Concentration-dependent opposite dual effects.
|
Clin Immunol
|
2009
|
0.85
|
|
50
|
Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients.
|
AIDS Res Hum Retroviruses
|
2006
|
0.84
|
|
51
|
Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.
|
AIDS Res Hum Retroviruses
|
2012
|
0.84
|
|
52
|
Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals.
|
PLoS One
|
2012
|
0.83
|
|
53
|
Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study.
|
J Acquir Immune Defic Syndr
|
2004
|
0.83
|
|
54
|
Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.
|
Hum Vaccin Immunother
|
2013
|
0.83
|
|
55
|
Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
|
J Antimicrob Chemother
|
2012
|
0.83
|
|
56
|
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
|
AIDS Res Hum Retroviruses
|
2010
|
0.82
|
|
57
|
Expression and function of the IL-2 receptor in activated human plasmacytoid dendritic cells.
|
Eur J Immunol
|
2007
|
0.82
|
|
58
|
Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.
|
Vaccine
|
2009
|
0.82
|
|
59
|
Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS.
|
Immunogenetics
|
2005
|
0.82
|
|
60
|
Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.
|
AIDS
|
2015
|
0.82
|
|
61
|
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
|
AIDS
|
2007
|
0.82
|
|
62
|
Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
|
Antivir Ther
|
2004
|
0.81
|
|
63
|
Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.
|
AIDS Res Hum Retroviruses
|
2012
|
0.81
|
|
64
|
HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.
|
Vaccine
|
2011
|
0.81
|
|
65
|
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
|
Antivir Ther
|
2004
|
0.81
|
|
66
|
Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV.
|
Immunol Cell Biol
|
2009
|
0.81
|
|
67
|
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.
|
Antivir Ther
|
2002
|
0.81
|
|
68
|
Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection.
|
AIDS
|
2002
|
0.80
|
|
69
|
Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy.
|
Antivir Ther
|
2003
|
0.80
|
|
70
|
Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection.
|
AIDS
|
2005
|
0.80
|
|
71
|
[Specialized home care for infectious disease. Experience from 1995 to 2002].
|
Enferm Infecc Microbiol Clin
|
2007
|
0.79
|
|
72
|
Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
|
Antivir Ther
|
2003
|
0.79
|
|
73
|
Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis.
|
Clin Infect Dis
|
2011
|
0.79
|
|
74
|
Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients.
|
Diagn Microbiol Infect Dis
|
2010
|
0.79
|
|
75
|
[Inflammatory response in elderly patients with bacteremia].
|
Enferm Infecc Microbiol Clin
|
2008
|
0.78
|
|
76
|
Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion.
|
Immunology
|
2006
|
0.78
|
|
77
|
[Comparison of three methods to calculate adherence in patients receiving antiretroviral treatment].
|
Enferm Infecc Microbiol Clin
|
2002
|
0.78
|
|
78
|
Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
|
J Antimicrob Chemother
|
2008
|
0.78
|
|
79
|
Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation.
|
Immunology
|
2009
|
0.77
|
|
80
|
Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.
|
AIDS Rev
|
2014
|
0.77
|
|
81
|
Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption.
|
Clin Infect Dis
|
2004
|
0.77
|
|
82
|
Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
|
AIDS
|
2007
|
0.77
|
|
83
|
Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial.
|
AIDS Res Hum Retroviruses
|
2014
|
0.76
|
|
84
|
Evaluation of the Roche COBAS® TaqMan® HIV-1 test for quantifying HIV-1 RNA in infected cells and lymphoid tissue.
|
J Virol Methods
|
2011
|
0.76
|
|
85
|
[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002].
|
Enferm Infecc Microbiol Clin
|
2002
|
0.76
|
|
86
|
Effects of different antigenic stimuli on thymic function and interleukin-7/CD127 system in patients with chronic HIV infection.
|
J Acquir Immune Defic Syndr
|
2014
|
0.76
|
|
87
|
Short Communication: Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption.
|
AIDS Res Hum Retroviruses
|
2008
|
0.76
|
|
88
|
Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.
|
Vaccine
|
2011
|
0.75
|
|
89
|
Antiretroviral therapy for HIV: do subtypes matter?
|
Clin Infect Dis
|
2011
|
0.75
|
|
90
|
Association study of lipoprotein(a) genetic markers, traditional risk factors, and coronary heart disease in HIV-1-infected patients.
|
Front Immunol
|
2012
|
0.75
|
|
91
|
Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
|
AIDS
|
2005
|
0.75
|
|
92
|
Twenty years of boosting antiretroviral agents: where are we today?
|
AIDS
|
2015
|
0.75
|
|
93
|
Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis.
|
Antivir Ther
|
2002
|
0.75
|
|
94
|
HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.
|
Curr Med Chem
|
2014
|
0.75
|
|
95
|
[Clinical management of acute and chronic human immunodeficiency virus infection before starting antiretroviral treatment].
|
Enferm Infecc Microbiol Clin
|
2011
|
0.75
|